Pre-made Toralizumab benchmark antibody (Whole mAb, anti-CD40LG therapeutic antibody, Anti-CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/TRAP/gp39/hCD40L Antibody) for drug discovery and mechanism of action (MOA) research

Anti-CD40LG therapeutic antibody (Pre-made Toralizumab biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Toralizumab (IDEC 131) was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenström's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-1026-1mg	1mg	3090
GMP-Bios-INN-1026-10mg	10mg	Inquiry
GMP-Bios-INN-1026-100mg	100mg	Inquiry
GMP-Bios-INN-1026-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Toralizumab Biosimilar, Whole Mab, Anti-Cd40Lg Antibody: Anti-CD154/CD40L/HIGM1/IGM/IMD3/T-BAM/TNFSF5/TRAP/gp39/hCD40L therapeutic antibody
INN Name	Toralizumab
Target	CD40LG
Format	Whole mAb
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	IgG1 - kappa
VD LC	IgG1 - kappa
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Biogen, Inc. (Cambridge MA USA) / Eisai Co. Ltd. (Tokyo Japan)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0